• Ultragenyx Pharmaceutical (NasdaqGS:RARE) faces multiple securities class action lawsuits tied to its setrusumab program.
• Complaints follow disclosures that the Phase III Orbit and Cosmic studies did not meet their primary endpoints.
• Plaintiffs allege management made misleading statements about setrusumab efficacy and risks, citing sharp investor losses after the trial updates.

For investors watching RARE, the legal challenges come after a tough share price stretch, with the stock at $20.18 and showing a 54.4% decline over the past year and an 85.9% decline over five years. Returns of a 15.5% decline over the past week and a 10.3% decline over the past month highlight how quickly sentiment has shifted around the setrusumab story.

These lawsuits add another layer of uncertainty around Ultragenyx Pharmaceutical, on top of the clinical questions raised by the Phase III outcomes. As the cases progress, investors are likely to focus closely on new disclosures, any changes in setrusumab plans, and how management addresses the allegations in public communications.

Stay updated on the most important news stories for Ultragenyx Pharmaceutical by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ultragenyx Pharmaceutical.

The securities class actions land at a sensitive time for Ultragenyx, as the failed Phase III setrusumab trials sit alongside sizeable losses and a cost-cutting plan. For 2025, the company reported revenue of US$673 million and a net loss of US$575 million, and it is targeting profitability in 2027 while reducing its workforce by 10%, or about 130 employees. Legal proceedings can be lengthy and costly, and investors will often think about two buckets of impact here: potential cash costs if any settlement or judgment is ultimately required, and the management time and distraction that can come with defending multiple cases.

How This Fits Into The Ultragenyx Pharmaceutical Narrative

• The restructuring plan and focus on “largest value drivers” echo the narrative that Ultragenyx is trying to tighten its path to 2027 profitability, which aligns with efforts to concentrate on late-stage assets like UX111 and other gene therapies.
• The lawsuits focused on setrusumab directly challenge earlier confidence in a broad rare-disease pipeline as a clean growth engine, and highlight the execution and regulatory risks that were already cited as key threats in the narrative.
• The narrative centers heavily on regulatory progress and commercial execution for gene therapies such as UX111, but it does not fully reflect the added legal overhang and potential financial impact from securities litigation tied to past disclosures.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Ultragenyx Pharmaceutical to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The company is still loss making, with a 2025 net loss of US$575 million, so any legal costs or settlement payments would come on top of an already heavy cash burn profile.
• ⚠️ Multiple class actions alleging misleading statements about trial design and data reliability introduce governance and disclosure risk, which can affect investor confidence until cases are resolved.
• 🎁 Revenue reached US$673 million in 2025 and 2026 guidance points to US$730 million to US$760 million, which some investors may see as evidence that the existing commercial portfolio is still gaining traction despite the setrusumab setback.
• 🎁 Management is cutting expenses, including a 10% workforce reduction, and reiterating a profitability goal for 2027, which provides a clear if ambitious financial target for holders to track.

What To Watch Going Forward

From here, the key things to watch are any concrete disclosures on legal exposure, including whether insurers are expected to cover a meaningful portion of potential costs, and how frequently management updates the market on case progress. On the operating side, investors may focus on whether Ultragenyx can stay on its revenue guidance range for 2026 while trimming expenses, and whether pipeline programs like UX111 move through the US FDA review as planned. Updates on cost savings from the restructuring, as well as commentary on cash runway on future earnings calls, will be important context for judging how much room the company has to absorb legal and clinical setbacks.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Ultragenyx Pharmaceutical, head to the community page for Ultragenyx Pharmaceutical to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.